First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Biologics: Targets and Therapy ◽

10.2147/btt.s26558 ◽

2012 ◽

pp. 337 ◽

Cited By ~ 4

Author(s):

Joel Neal ◽

Kim-Son H. Nguyen

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

Phase I Study of Apatinib in Combination with Gefitinib As First-Line Treatment in Patients with EGFR-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3454715 ◽

2019 ◽

Author(s):

Zhonghan Zhang ◽

Yang Zhang ◽

Fan Luo ◽

Yuxiang Ma ◽

Wenfeng Fang ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Phase I Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

Thoracic Cancer ◽

10.1111/1759-7714.13462 ◽

2020 ◽

Author(s):

Po‐Lan Su ◽

Chian‐Wei Chen ◽

Yi‐Lin Wu ◽

Chien‐Chung Lin ◽

Wu‐Chou Su

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

Expert Review of Anticancer Therapy ◽

10.1586/era.09.3 ◽

2009 ◽

Vol 9 (4) ◽

pp. 425-435 ◽

Cited By ~ 19

Author(s):

Marcello Tiseo ◽

Marco Bartolotti ◽

Francesco Gelsomino ◽

Andrea Ardizzoni

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Histologic Subtype ◽

First Line Treatment

Download Full-text

Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

Translational Lung Cancer Research ◽

10.21037/tlcr.2017.10.10 ◽

2017 ◽

Vol 6 (S1) ◽

pp. S62-S66 ◽

Cited By ~ 4

Author(s):

Chong-Kin Liam

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer

Clinical and Translational Medicine ◽

10.1002/ctm2.33 ◽

2020 ◽

Vol 10 (2) ◽

Author(s):

Zhonghan Zhang ◽

Yang Zhang ◽

Fan Luo ◽

Yuxiang Ma ◽

Wenfeng Fang ◽

...

Keyword(s):

Lung Cancer ◽

Pilot Study ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Dual Blockade ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.05.006 ◽

2021 ◽

Author(s):

Hongyun Zhao ◽

Wenxiu Yao ◽

Xuhong Min ◽

Kangsheng Gu ◽

Guohua Yu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

P2.14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.1819 ◽

2019 ◽

Vol 14 (10) ◽

pp. S842-S843

Author(s):

J. Skřičková ◽

P. Májková ◽

M. Bařinová ◽

M. Pešek ◽

V. Kolek ◽

...

Keyword(s):

Lung Cancer ◽

Czech Republic ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

The Czech Republic ◽

First Line Treatment

Download Full-text

Gefitinib (G) and Pemetrexed (Pem) as a First Line Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase II Study

Annals of Oncology ◽

10.1016/s0923-7534(20)33852-7 ◽

2012 ◽

Vol 23 ◽

pp. ix412-ix413 ◽

Cited By ~ 1

Author(s):

N. Yoshimura ◽

K. Matsuura ◽

S. Mitsuoka ◽

K. Asai ◽

Y. Tochino ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer

Expert Opinion on Biological Therapy ◽

10.1080/14712598.2021.1869209 ◽

2020 ◽

pp. 1-7

Author(s):

Danilo Rocco ◽

Luigi Della Gravara ◽

Ciro Battiloro ◽

Cesare Gridelli

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

EGFR tyrosine kinase inhibitors in first-line treatment of elderly patients with advanced non-small-cell lung cancer

Journal of Geriatric Oncology ◽

10.1016/j.jgo.2014.09.050 ◽

2014 ◽

Vol 5 ◽

pp. S33-S34

Author(s):

M. Knetki-Wroblewska ◽

A. Pluzanski ◽

M. Krzakowski

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitors ◽

First Line Treatment

Download Full-text